Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer.

Tuberculous Spondylitis following Intravesical Bacillus Calmette-Guerin for Bladder Cancer.

Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin.

Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients.

Intravesical therapy for bladder cancer.

Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.

Adjuvant intravesical therapy for superficial bladder cancer.

Intravesical bacillus Calmette-Guerin for patients with high-risk superficial bladder cancer.

Infected Aortic Aneurysm caused by Mycobacterium bovis after Intravesical Bacillus Calmette-Guérin Treatment for Bladder Cancer.

Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma.

Fatal sepsis following peripheral intravenous cannula embolus.

Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder Cancer.

Clinical characteristics of Japanese patients with reactive arthritis following intravesical BCG therapy for bladder cancer.

Is bladder tumor location associated with prostate cancer detection after intravesical bacillus Calmette-Guérin instillation?

Clinical study of prognostic factors of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin.

Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.

Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy.

Bladder uptake of liposomes after intravesical administration occurs by endocytosis.

Reactive arthritis induced by intravesical BCG therapy for bladder cancer.

[Intravesical gemcitabine for non-muscle invasive bladder cancer].

Emerging intravesical therapies for management of nonmuscle invasive bladder cancer.

Comparison of intravesical bacillus Calmette-Guerin and mitomycin C administration for non-muscle invasive bladder cancer: A meta-analysis and systematic review.

Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.

Development of Predictive Value of Urinary Cytokine Profile Induced During Intravesical Bacillus Calmette-Guérin Instillations for Bladder Cancer.

Suggest Documents

Tuberculous Spondylitis following Intravesical Bacillus Calmette-Guerin for Bladder Cancer.

Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin.

Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients.

Intravesical therapy for bladder cancer.

Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.

Adjuvant intravesical therapy for superficial bladder cancer.

Intravesical bacillus Calmette-Guerin for patients with high-risk superficial bladder cancer.

Infected Aortic Aneurysm caused by Mycobacterium bovis after Intravesical Bacillus Calmette-Guérin Treatment for Bladder Cancer.

Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma.

Fatal sepsis following peripheral intravenous cannula embolus.

Mycobacterial Osteomyelitis of the Spine Following Intravesical BCG Therapy for Bladder Cancer.

Clinical characteristics of Japanese patients with reactive arthritis following intravesical BCG therapy for bladder cancer.

Is bladder tumor location associated with prostate cancer detection after intravesical bacillus Calmette-Guérin instillation?

Clinical study of prognostic factors of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin.

Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.

Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy.

Bladder uptake of liposomes after intravesical administration occurs by endocytosis.

Reactive arthritis induced by intravesical BCG therapy for bladder cancer.

[Intravesical gemcitabine for non-muscle invasive bladder cancer].

Emerging intravesical therapies for management of nonmuscle invasive bladder cancer.

Comparison of intravesical bacillus Calmette-Guerin and mitomycin C administration for non-muscle invasive bladder cancer: A meta-analysis and systematic review.

Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.

Development of Predictive Value of Urinary Cytokine Profile Induced During Intravesical Bacillus Calmette-Guérin Instillations for Bladder Cancer.

Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer.

Recommend Documents

Follow Us